AOC 1020 + Placebo
Phase 1/2ActiveDevelopment Stage
FSHD
FSHD, FSHD1, FSHD2, FMD, FMD2, Fascioscapulohumeral Muscular Dystrophy, Fascioscapulohumeral Muscular Dystrophy Type 1, Fascioscapulohumeral Muscular Dystrophy Type 2, Dystrophies, Facioscapulohumeral Muscular, Dystrophy, Facioscapulohumeral Muscular, Facioscapulohumeral Muscular Dystrophy 1, Facioscapulohumeral Muscular Dystrophy 2, Facio-Scapulo-Humeral Dystrophy, Atrophy, Facioscapulohumeral, Atrophies, Facioscapulohumeral, Facioscapulohumeral Atrophy, Muscular Dystrophies, Muscular Dystrophy, Facioscapulohumeral, FSH Muscular Dystrophy, Landouzy Dejerine Dystrophy, Landouzy-Dejerine Muscular Dystrophy, Dystrophies, Landouzy-Dejerine, Dystrophy, Landouzy-Dejerine, Landouzy-Dejerine Syndrome, Muscular Dystrophy, Landouzy Dejerine, Progressive Muscular Dystrophy, FSH
Apr 4, 2023 → Apr 1, 2027
About AOC 1020 + Placebo
AOC 1020 + Placebo is a phase 1/2 stage product being developed by Avidity Biosciences for FSHD. The current trial status is active. This product is registered under clinical trial identifier NCT05747924. Target conditions include FSHD, FSHD1, FSHD2.
Hype Score Breakdown
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05747924 | Phase 1/2 | Active |
Competing Products
7 competing products in FSHD
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Placebo + RO7204239 | Roche | Phase 2 | 52 |
| AOC 1020 | Avidity Biosciences | Phase 2 | 49 |
| Losmapimod oral tablet + Placebo oral tablet | Fulcrum Therapeutics | Phase 2 | 44 |
| Losmapimod + Placebo oral tablet | Fulcrum Therapeutics | Phase 3 | 69 |
| Losmapimod | Fulcrum Therapeutics | Phase 2 | 44 |
| ATYR1940 | aTyr Pharma | Phase 1/2 | 33 |
| Placebo + ATYR1940 | aTyr Pharma | Phase 1/2 | 33 |